Navigation Links
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Date:11/30/2007

INDIANAPOLIS, Nov. 30 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Cymbalta(R) (duloxetine HCl) for the maintenance treatment of major depressive disorder (MDD) in adults.

"Relapse, the re-emergence of depressive symptoms after a successful treatment of depression, is a significant clinical concern," says Doug Williamson, M.D., Cymbalta associate medical director for Eli Lilly and Company. "This approval from the FDA is important because data from our Cymbalta clinical trial demonstrate that continuing to treat the patient delays the time to possible relapse."

Treating the broad range of depression symptoms may minimize the presence of residual symptoms (e.g., anxiety, guilt and low self-esteem) and can help delay the time to relapse(1). Common symptoms of depression can include sadness, loss of interest, fatigue, changes in appetite or weight, or bodily aches and pains.

"Once an episode of depression has been successfully treated, it is imperative that the symptoms do not return," said Lauren Marangell, M.D., an internationally recognized expert on depression and other mood disorders and a distinguished scholar at Lilly. "The American Psychiatric Association has recommended maintenance of antidepressant treatment to help decrease the chance of relapse."

The efficacy and safety of Cymbalta for maintenance treatment of major depression was established in a double-blind, placebo-controlled clinical trial. Patients with major depression in the trial (533 patients) received Cymbalta 60 mg once daily. After 12 weeks, 278 patients met the criteria for entering the continuation phase and were randomly assig
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
6. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...Nov. 9 ARmark Authentication Techn...n alliance in the development and introduction of ...on technology that incorporates microscopic covert...gs of solid oral dosage forms (SODFs) to prevent c...usive rights to market ARmark,s micro-tags for tab...
(Date:11/9/2009)...SCO, Calif., Nov. 9 Anes... November 5, 2009, it received a letter from The N... Nasdaq Hearing Panel has granted Anesiva,s reques...t subject to the condition that Anesiva shall have...posed merger (the "Merger") contemplated by the Ag...
(Date:11/9/2009)..., Nov. 9 Caliper Life Sc...of tools and services for drug discovery and life ...r Discovery Alliances and Services (CDAS) unit has...llion under its contract with the Environmental Pr...ing program. This new task order increases the cu...
Breaking Medicine Technology:ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 2ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 3Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 2Anesiva Receives Positive Nasdaq Hearing Panel Determination for Continued Listing 3Caliper Awarded New Task Order for EPA ToxCast Program 2Caliper Awarded New Task Order for EPA ToxCast Program 3Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane disrupting Agent EP 100 in Patients with Cancer 13972 1Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane disrupting Agent EP 100 in Patients with Cancer 13972 2Esperance Pharmaceuticals Announces Initiation of Clinical Studies of its Novel Membrane disrupting Agent EP 100 in Patients with Cancer 13972 3Girl in Iconic Vietnam War Photo Brings Message of Hope 56745 1Girl in Iconic Vietnam War Photo Brings Message of Hope 56745 2Girl in Iconic Vietnam War Photo Brings Message of Hope 56745 3Girl in Iconic Vietnam War Photo Brings Message of Hope 56745 4VitaPath Genetics Raises 246M in Series A Round 56742 1VitaPath Genetics Raises 246M in Series A Round 56742 2
...RNewswire-FirstCall/ -- Auxilium,Pharmaceuticals, ...,Executive Officer and President, and Mr. Jim Fick... in the 2007 CEUT Emerging,Growth Opportunities Co...at the Mandarin Oriental Hotel in New York City. M...e Company and its product,pipeline at 4:30 PM East...
...uly 10, 2007 /CNW/ - Protox,Therapeutics Inc. (TSX... from its Phase 1 clinical trial evaluating ,PRX30...ancer,following radiation failure. The trial resu...ed and shows promising signs,of therapeutic activi... , ,"The completion of the PRX302 Phase 1 tri...
Other Medicine Technology:Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference 2Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging,Growth Opportunities Conference 3Protox Announces Positive Clinical Data from Prostate Cancer Study 2Protox Announces Positive Clinical Data from Prostate Cancer Study 3Protox Announces Positive Clinical Data from Prostate Cancer Study 4Protox Announces Positive Clinical Data from Prostate Cancer Study 5
(Date:11/9/2009)...bbits implanted with new cells regained sexual fun... (HealthDay News) -- Researchers were able to rest...s by growing new penile tissue in the lab and impl...n application is a ways off, researchers say the t...ctile dysfunction in men. , "We were able to sh...
(Date:11/9/2009)..., SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/...al.com , announced today that Novartis, a US$41 bi...ng an 85% stake in HTDS, H1N1 Vaccine partner, Zhe...S$125 million. Novartis of Switzerland will begin ...aims: the company will dramatically increase its i...
(Date:11/9/2009)... Tomorrow may be too late w... condition, according to TOPS Club, Inc. (Take Off...rt organization. , (Vocus...n it comes to preventing or improving a diabetes c...ounds Sensibly), the nonprofit weight-loss support...
(Date:11/9/2009)... New study highlights posit...th , Rosemont, IL (Vocus)...ase and bone health decreases. Recent research has...m supplements to help prevent these issues. Howeve...issue of Sports Health: A Multidisciplinary Appro...
(Date:11/9/2009)..., SANTA MONICA, Calif., Nov. 9 A...ndation joined philosophy on Saturday to rai...support services throughout California by building...lters. Enough kits were created to give one to ea...ed in one of Los Angeles County,s domestic violenc...
Breaking Medicine News(10 mins):Health News:Scientists Grow New Penile Tissue in the Lab 2Health News:Scientists Grow New Penile Tissue in the Lab 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3
...Ageing populations are an increasing issue for the... sixty is growing plus there has been a rise in ol...ose living with children or relatives. A new study...ness of older people and how it varies within Euro...
...hind-the-counter, dispensing would bypass doctors ... 14 (HealthDay News) -- During a day-long public h... to be sold by pharmacists without a prescription,...est groups. , But at the day,s end, the FDA offici...
... FRANCISCO, Nov. 14 Some 225 healthcare,organizat...ived recognition,for their outstanding websites at... during the Eleventh Annual Healthcare Internet Co...healthcare and,the Internet judged the entries. T...
...NE, Pa., Nov. 14 Escalon Medical Corp.,(Nasdaq: ...t quarter ended,September 30, 2007. For the first...revenue,of $6,893,271, a 4% decrease from the $7,1...ich decreased 3% and 2%,respectively, compared wit...
...COUVER, Nov. 14 /PRNewswire-FirstCall/ - Dragon Ph...P) today announced that it has entered an,agreemen...PO business which,accounted for less than 3% of Dr...h potential, if not downward trend, during,the nex...
...LEY, N.J., Nov. 14 Roche announced today,that the...ved MIRCERA,(methoxy polyethylene glycol-epoetin b...hronic renal failure (CRF) in adults, including pa...s-stimulating agent (ESA) to provide correction of...
Other Medicine News:Health News:Living arrangements, health and well-being: A European perspective 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 2Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 3Health News:FDA Hears Pros, Cons of Pharmacist-to-Patient Drug Sales 4Health News:Epilepsy.com Wins Silver for Best Patient Care/Disease Management Website at the 2007 eHealthcare Leadership Awards - Honored at Healthcare Internet Conference in Las Vegas 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 2Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 3Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 4Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 5Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 6Health News:Escalon(R) Reports First Quarter Fiscal 2008 Results 7Health News:Dragon Sells EPO Business; Focus on Antibiotic Core Business 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 3
...is a purified and lyophilized bovine dermal collag...s lightly cross-linked, sterile, non-pyrogenic, an...erent property of collagen, is largely dependent o... helical structure of native collagen is preserved...
...able microhematocrit determinations. Although the ... than most competitive 6 tube centrifuges. The hig...cluded reader is adjustable, allowing accurate rea...ter operation than many similiar units, the Micros...
... engineering and design specifications, Smith & Ne...eamless integration with existing inventories and ... procedures (AO method). However, the TC-100 syste... range of components, increased cost-effectiveness...
... most technically demanding specialties within ort...ffers the highly specialized surgeon a complete an...pelvis and acetabulum. , ,Joel Matta, MD, world r...ner of this system. The system features specific r...
Medicine Products: